AZD1208

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Acute Myeloid LeukemiaAdvanced Solid MalignanciesMalignant Lymphoma

Phase 1

Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients

TerminatedNCT01489722

AstraZenecaAcute Myeloid Leukemia

Start: 2012-02-29End: 2014-05-31Updated: 2015-08-11

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

CompletedNCT01588548

AstraZenecaAdvanced Solid Malignancies, Malignant Lymphoma

Start: 2012-07-31End: 2014-07-31Updated: 2015-11-04